Publication Year

 Publication Title

 2020  

Circulating Cell-Free BRAF V600E During Chemotherapy Is Associated with Prognosis of Children with Langerhans Cell Histiocytosis. Haematologica; Vol. 105 No. 9 (2020): September, 2020 ; LINK

 2019

Clinical responses and persistent BRAFV600E(+) blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019; 133(15):1691-1694. LINK

Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis. Pediatric Research 2019; 85(6):856-864. LINK

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.  Journal of Clinical Oncology 37, no. 31 (Nov 1 2019): 2857-65; LINK 

 2018

Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatric Blood and Cancer 2018;65(1) LINK

Langerhans cell histiocytosis. New England Journal of Medicine 379, no. 9 (Aug 30 2018): 856-68 LINK

Origin for LCH-Associated Neurodegeneration and Mass Lesions. Cancer 124, no. 12 (Jun 15 2018): 2607-20. LINK

 2017

Circulating Cell-Free BRAF(V600E) as a Biomarker in Children with Langerhans Cell Histiocytosis. British Journal of Haematology 178, no. 3 (Aug 2017): 457-67. LINK 

 2016

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. Journal of Clinical Oncology 34, no. 25 (Sep 1 2016): 3023-30. LINK

 2015

Biological and Clinical Significance of Somatic Mutations in Langerhans Cell Histiocytosis and Related Histiocytic Neoplastic Disorders. Hematology, American Society of Hematology Education Program 2015 (2015): 559-64. LINK

Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015; 126(12): 1415-1423. LINK

 2013

Therapy prolongation improves outcome in multi-system Langerhans cell histiocytosis.  Blood. 2013; 121(25):5006-5014. LINK